196 related articles for article (PubMed ID: 38051455)
41. Real world experience of treatment and outcome in ALK-rearranged metastatic nonsmall cell lung cancer: A multicenter study from India.
Patel A; Batra U; Prasad KT; Dabkara D; Ghosh J; Sharma M; Singh N; Suresh P; Jain P; Malik PS; Choudhary P; Ganguly S; Khurana S; Ms S; Bothra S; Muthu V; Biswas B
Curr Probl Cancer; 2020 Jun; 44(3):100571. PubMed ID: 32234264
[TBL] [Abstract][Full Text] [Related]
42. Clinical data from the real world: Efficacy analysis of ceritinib (450mg) in ALK-rearrangement non-small-cell lung cancer patients with brain metastases in China.
Qiu Z; Xian X; Liu C; Yu M; Lin F; Huang M; Wang K
J Cancer Res Ther; 2022 Apr; 18(2):516-524. PubMed ID: 35645123
[TBL] [Abstract][Full Text] [Related]
43. Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3).
Popat S; Liu G; Lu S; Song G; Ma X; Yang JC
Future Oncol; 2021 Nov; 17(32):4237-4247. PubMed ID: 34423676
[TBL] [Abstract][Full Text] [Related]
44. The efficacy and safety of ALK inhibitors in the treatment of ALK-positive non-small cell lung cancer: A network meta-analysis.
Fan J; Fong T; Xia Z; Zhang J; Luo P
Cancer Med; 2018 Oct; 7(10):4993-5005. PubMed ID: 30230699
[TBL] [Abstract][Full Text] [Related]
45. Durable brain response with pulse-dose crizotinib and ceritinib in ALK-positive non-small cell lung cancer compared with brain radiotherapy.
Dudnik E; Siegal T; Zach L; Allen AM; Flex D; Yust-Katz S; Limon D; Hirsch FR; Peled N
J Clin Neurosci; 2016 Apr; 26():46-9. PubMed ID: 26677785
[TBL] [Abstract][Full Text] [Related]
46. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
Gettinger SN; Bazhenova LA; Langer CJ; Salgia R; Gold KA; Rosell R; Shaw AT; Weiss GJ; Tugnait M; Narasimhan NI; Dorer DJ; Kerstein D; Rivera VM; Clackson T; Haluska FG; Camidge DR
Lancet Oncol; 2016 Dec; 17(12):1683-1696. PubMed ID: 27836716
[TBL] [Abstract][Full Text] [Related]
47. Clinical outcomes of
Hansen KH; Johansen JS; Urbanska EM; Meldgaard P; Hjorth-Hansen P; Kristiansen C; Stelmach M; Santoni-Rugiu E; Ulhøi MP; Dydensborg AB; Dünweber C; Andersen JL
Acta Oncol; 2023 Dec; 62(12):1775-1783. PubMed ID: 37815923
[TBL] [Abstract][Full Text] [Related]
48. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
Shaw AT; Yeap BY; Solomon BJ; Riely GJ; Gainor J; Engelman JA; Shapiro GI; Costa DB; Ou SH; Butaney M; Salgia R; Maki RG; Varella-Garcia M; Doebele RC; Bang YJ; Kulig K; Selaru P; Tang Y; Wilner KD; Kwak EL; Clark JW; Iafrate AJ; Camidge DR
Lancet Oncol; 2011 Oct; 12(11):1004-12. PubMed ID: 21933749
[TBL] [Abstract][Full Text] [Related]
49. Overall Survival of Patients With
Tsimafeyeu I; Moiseenko F; Orlov S; Filippova E; Belonogov A; Nebesnykh A; Khalimov A; Karabina E; Shikina V; Abdelgafur A; Statsenko G; Titova I; Isaichikov D; Makarnyaeva G; Mordovskiy A; Barkovskaya O; Smirnov A; Gikalo M; Savelov N; Kosov D; Imyanitov E; Demidova I; Tjulandin S
J Glob Oncol; 2019 May; 5():1-7. PubMed ID: 31095455
[TBL] [Abstract][Full Text] [Related]
50. Effect of alectinib versus crizotinib on progression-free survival, central nervous system efficacy and adverse events in ALK-positive non-small cell lung cancer: a systematic review and meta-analysis.
Yang YL; Xiang ZJ; Yang JH; Wang WJ; Xiang RL
Ann Palliat Med; 2020 Jul; 9(4):1782-1796. PubMed ID: 32527124
[TBL] [Abstract][Full Text] [Related]
51. Efficacy of different sequential patterns after crizotinib progression in advanced anaplastic lymphoma kinase-positive non-small cell lung cancer.
Ma X; Yang S; Zhang K; Xu J; Lv P; Gao H; Qin H; Wang H; Liu X
Thorac Cancer; 2022 Jun; 13(12):1788-1794. PubMed ID: 35560808
[TBL] [Abstract][Full Text] [Related]
52. [Whole-process Management of Treatment of Advanced ALK Positive Non-small Cell Lung Cancer: A Case Report].
Bai H; Han Y; Niu Y; Zhang M
Zhongguo Fei Ai Za Zhi; 2021 Aug; 24(8):598-604. PubMed ID: 34344501
[TBL] [Abstract][Full Text] [Related]
53. Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer.
Ock CY; Yoo SH; Keam B; Kim M; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS
Korean J Intern Med; 2019 Sep; 34(5):1116-1124. PubMed ID: 29950554
[TBL] [Abstract][Full Text] [Related]
54. The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib.
Patil T; Smith DE; Bunn PA; Aisner DL; Le AT; Hancock M; Purcell WT; Bowles DW; Camidge DR; Doebele RC
J Thorac Oncol; 2018 Nov; 13(11):1717-1726. PubMed ID: 29981925
[TBL] [Abstract][Full Text] [Related]
55. Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice.
Jamme P; Descarpentries C; Gervais R; Dansin E; Wislez M; Grégoire V; Richard N; Baldacci S; Rabbe N; Kyheng M; Kherrouche Z; Escande F; Copin MC; Cortot AB
Clin Lung Cancer; 2019 Jul; 20(4):297-304.e1. PubMed ID: 31147208
[TBL] [Abstract][Full Text] [Related]
56. Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer.
Kang J; Chen HJ; Zhang XC; Su J; Zhou Q; Tu HY; Wang Z; Wang BC; Zhong WZ; Yang XN; Chen ZH; Ding Y; Wu X; Wang M; Fu JG; Yang Z; Zhang X; Shao YW; Wu YL; Yang JJ
Thorac Cancer; 2018 Sep; 9(9):1093-1103. PubMed ID: 29978950
[TBL] [Abstract][Full Text] [Related]
57. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.
Mok T; Camidge DR; Gadgeel SM; Rosell R; Dziadziuszko R; Kim DW; Pérol M; Ou SI; Ahn JS; Shaw AT; Bordogna W; Smoljanović V; Hilton M; Ruf T; Noé J; Peters S
Ann Oncol; 2020 Aug; 31(8):1056-1064. PubMed ID: 32418886
[TBL] [Abstract][Full Text] [Related]
58. Detection of Nonreciprocal/Reciprocal ALK Translocation as Poor Predictive Marker in Patients With First-Line Crizotinib-Treated ALK-Rearranged NSCLC.
Zhang Y; Zeng L; Zhou C; Li Y; Wu L; Xia C; Jiang W; Hu Y; Liao D; Xiao L; Liu L; Yang H; Xiong Y; Guan R; Lizaso A; Mansfield AS; Yang N
J Thorac Oncol; 2020 Jun; 15(6):1027-1036. PubMed ID: 32112982
[TBL] [Abstract][Full Text] [Related]
59. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study.
Zhou C; Kim SW; Reungwetwattana T; Zhou J; Zhang Y; He J; Yang JJ; Cheng Y; Lee SH; Bu L; Xu T; Yang L; Wang C; Liu T; Morcos PN; Lu Y; Zhang L
Lancet Respir Med; 2019 May; 7(5):437-446. PubMed ID: 30981696
[TBL] [Abstract][Full Text] [Related]
60. Simultaneous VENTANA IHC and RT-PCR testing of ALK status in Chinese non-small cell lung cancer patients and response to crizotinib.
Xu CW; Wang WX; Chen YP; Chen Y; Liu W; Zhong LH; Chen FF; Zhuang W; Song ZB; Chen XH; Huang YJ; Guan YF; Yi X; Lv TF; Zhu WF; Lu JP; Wang XJ; Shi Y; Lin XD; Chen G; Song Y
J Transl Med; 2018 Apr; 16(1):93. PubMed ID: 29642919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
